# A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

Source: https://onco.cc/trials/nct07581002/  
OnCo record `nct07581002` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Pivekimab sunirine, Venetoclax and Azacitidine in acute myeloid leukaemia, run by AbbVie, now recruiting.

## Summary

A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) is a phase 2/3 interventional study registered as NCT07581002 by AbbVie, with 660 participants planned, started 2026-06-30 and due to reach its primary completion in 2032-06. Interventions recorded: Pivekimab Sunirine, Venetoclax, Azacitidine and Matching Placebo for PVEK.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07581002
- Phase: 2/3
- Setting: A Randomized Phase 2/3 Study Evaluating the Safety and Efficacy of Pivekimab Sunirine (PVEK) in Combination With Venetoclax and Azacitidine in Adult Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible to Receive Intensive Chemotherapy
- Sponsor: AbbVie
- Enrolled: 660

## Sources

- ClinicalTrials.gov NCT07581002: https://clinicaltrials.gov/study/NCT07581002

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- drugs: [Azacitidine](https://onco.cc/drugs/azacitidine/), [Pivekimab sunirine](https://onco.cc/drugs/pivekimab-sunirine/), [Venetoclax](https://onco.cc/drugs/venetoclax/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/)

---
JSON: https://onco.cc/api/v1/entities/nct07581002.json